Literature DB >> 9044530

Estimating the completeness of prevalence based on cancer registry data.

R Capocaccia1, R De Angelis.   

Abstract

Prevalence data provided by cancer registries are generally biased, since the patients that were diagnosed before the starting of the registry's activity cannot be included in the statistics. The relevance of this incompleteness bias is estimated in this paper. Incidence and relative survival are modelled as parametric functions describing a wide class of cancer diseases. Prevalence estimates are then computed considering different hypotheses on disease reversibility. The ratio between the prevalence observed by the registry and the total estimated prevalence is used as an index of completeness. An analytical evaluation of this ratio, as a function of the parameters characterizing the observational process and the biological behaviour of the disease, is given.

Entities:  

Mesh:

Year:  1997        PMID: 9044530     DOI: 10.1002/(sici)1097-0258(19970228)16:4<425::aid-sim414>3.0.co;2-z

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

1.  Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations.

Authors:  S Panico; R Galasso; E Celentano; A V Ciardullo; L Frova; R Capocaccia; M Trevisan; F Berrino
Journal:  Am J Public Health       Date:  2000-09       Impact factor: 9.308

2.  Improved population-based probability of developing cancer when direct estimates of the cancer-free population are available.

Authors:  Arianna Simonetti; Angela Mariotto; Martin Krapcho; Eric J Feuer
Journal:  Lifetime Data Anal       Date:  2012-03-20       Impact factor: 1.588

3.  Getting cancer prevalence right: using state cancer registry data to estimate cancer survivors.

Authors:  William R Carpenter; Wei-Shi Yeh; Sara E Wobker; Paul A Godley
Journal:  Cancer Causes Control       Date:  2011-03-01       Impact factor: 2.506

4.  Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.

Authors:  Adah S Zhang; Quinn T Ostrom; Carol Kruchko; Lisa Rogers; David M Peereboom; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

5.  [Prevalence of cancer in the Guadalajara health area].

Authors:  J M Alonso Gordo; A Bárcena Marugán; D Jiménez Del Val; J J Palacios Rojo; C Royo Sánchez; J Urbina Torija
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

6.  Cancer prevalence in the United Kingdom: estimates for 2008.

Authors:  J Maddams; D Brewster; A Gavin; J Steward; J Elliott; M Utley; H Møller
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

7.  Prevalence of breast carcinoma in situ in the United States.

Authors:  Brian L Sprague; Amy Trentham-Dietz
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

8.  Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid.

Authors:  C Daniel Mullins; Jesse L Cooke; Junling Wang; Fadia T Shaya; Doren Van Hsu; Sandra Brooks
Journal:  J Natl Med Assoc       Date:  2004-06       Impact factor: 1.798

9.  Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry.

Authors:  Tomáš Pavlík; Ondřej Májek; Jan Mužík; Jana Koptíková; Lubomír Slavíček; Jindřich Fínek; David Feltl; Rostislav Vyzula; Ladislav Dušek
Journal:  BMC Public Health       Date:  2012-02-10       Impact factor: 3.295

10.  Projections of cancer prevalence in the United Kingdom, 2010-2040.

Authors:  J Maddams; M Utley; H Møller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.